Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536484 · ClinicalTrials.gov registry record · Phase 3
Fesoterodine Flexible Dose Study
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 896
- Enrollment target
NCT00536484: Completed Phase 3 study, sponsored by Pfizer.
NCT00536484 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 896 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00536484, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 896 participants
- Enrollment target
Study Summary
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.
Primary Outcome
The number of micturitions per 24 hours was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit. Change: mean at Week 12 minus mean at Baseline
Interventions
- DRUG Placebo
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00536484 record still lists
NCT00536484 is an interventional study that assigns participants to a tested intervention. The registered 896 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00536484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00536484 about?
NCT00536484 is a clinical study titled "Fesoterodine Flexible Dose Study". This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regim...
What is the current status of trial NCT00536484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 896 participants. The study started on 2007-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00536484?
The interventions under investigation include: Placebo (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00536484?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00536484's enrollment target sits among peer trials
896 361st of 2000 higher than 1,640 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia